Skip to content
Screener

Arvinas ARVN EPS (Diluted)

EPS (Diluted) at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$0.81-55.8%
LON
LeonaBio, Inc.LONA
-$1.73+26.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$0.62+34.7%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$0.22+62.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$0.96+49.5%
Immunome logo
ImmunomeIMNM
-$0.65-30.0%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars and shares in millions, except per share amounts) / Consolidated Statements of OperationsFor the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Income tax expense(0.1)(0.2)
Net (loss) income$(57.6)$82.9
(Loss) earnings per common share
Basic$(0.90)$1.14
Diluted$(0.90)$1.14
Weighted average common shares outstanding
Basic64.072.5
Diluted64.072.7

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's EPS (diluted)?
Arvinas (ARVN) reported EPS (diluted) of -$0.90 in Q1 2026.
How has Arvinas's EPS (diluted) changed year-over-year?
Arvinas's EPS (diluted) decreased by 178.9% year-over-year, from $1.14 to -$0.90.
What is the long-term trend for Arvinas's EPS (diluted)?
Over 4 years (2021 to 2025), Arvinas's EPS (diluted) has grown at a -26.1% compound annual growth rate (CAGR), from -$3.82 to -$1.14.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Arvinas's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude